All In Biotech

Drug Trial Radar · NCT00481169

Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women

A Multicenter, Double Blind, Randomized, Placebo and Raloxifene Controlled Study to Assess Safety and Efficacy of TSE-424 (Bazedoxifene Acetate) in the Prevention of Postmenopausal Osteoporosis

Last checked: Nov 20, 2026Latest source record: Aug 21, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,742 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,742

Actual

Start

Jul 2001

Primary completion

Jul 2004

Study completion Sep 2004

Sponsor

Sponsor type
Industry
First posted
Jun 1, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Prevention
Who can join
Female only, from 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether TSE-424 (bazedoxifene acetate), an investigational drug, is safe and effective in the prevention of osteoporosis in postmenopausal women.

Conditions

  • Osteoporosis

Interventions

  • Bazedoxifene Acetate (TSE-424)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The percent change from baseline in lumbar spine bone mineral density (BMD) after 24 months.Time frame: 24 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.